Evidence supporting the use of: Daidzein
For the health condition: Osteoporosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Daidzein is an isoflavone found predominantly in soy products and has been studied for its potential role in supporting bone health and treating osteoporosis, particularly in postmenopausal women. The mechanistic rationale is that daidzein can act as a phytoestrogen, binding to estrogen receptors and partially mimicking estrogen’s effects on bone metabolism. Since estrogen deficiency after menopause is a key driver of osteoporosis, compounds like daidzein have garnered scientific interest.

Several animal studies and in vitro experiments have demonstrated that daidzein can prevent bone loss, increase bone mineral density (BMD), and modulate bone turnover markers. Human studies are more limited and show mixed results. Some randomized controlled trials suggest that soy isoflavones (including daidzein) may modestly increase BMD or slow bone loss in postmenopausal women, while others show no significant benefit. Meta-analyses generally report small but statistically significant effects, though the clinical relevance is debated and the magnitude of benefit is less than that of conventional osteoporosis therapies.

Overall, the use of daidzein for osteoporosis is scientifically investigated and somewhat justified by evidence, but its effect size is modest and more research is needed to firmly establish efficacy and optimal usage. It is not considered a first-line therapy but may be used as adjunctive support, especially in populations with dietary soy intake.

More about Daidzein
More about Osteoporosis

Products containing Daidzein

We currently have no products on Vitabase that contain this ingredient.